Found: 88
Select item for more details and to access through your institution.
Long-term retention rates of anti-tumour necrosis factor and anti-interleukin-17 antibodies for patients with psoriatic arthritis.
- Published in:
- Modern Rheumatology, 2024, v. 34, n. 5, p. 1013, doi. 10.1093/mr/road111
- By:
- Publication type:
- Article
Association Between Biologic Exposure and the Risk of Depression in Patients with Psoriasis: A Retrospective Analysis of Large US Administrative Claims Data.
- Published in:
- 2024
- By:
- Publication type:
- Letter
Comparison of Real-World On-Label Treatment Persistence in Patients with Psoriatic Arthritis Receiving Guselkumab Versus Subcutaneous Tumor Necrosis Factor Inhibitors.
- Published in:
- Drugs - Real World Outcomes, 2024, v. 11, n. 3, p. 487, doi. 10.1007/s40801-024-00428-z
- By:
- Publication type:
- Article
A real-world retrospective study on biologics utilization in patients with psoriasis in Greece during the period 2015–2020.
- Published in:
- Archives of Dermatological Research, 2024, v. 316, n. 7, p. 1, doi. 10.1007/s00403-024-03147-1
- By:
- Publication type:
- Article
Adoption of newly FDA-approved targeted immunomodulatory therapies by dermatologists: a cross-sectional analysis of Medicare Part D claims from 2013 to 2018.
- Published in:
- Archives of Dermatological Research, 2023, v. 315, n. 3, p. 673, doi. 10.1007/s00403-022-02422-3
- By:
- Publication type:
- Article
Infliximab biosimilar-induced lupus nephritis: A case report.
- Published in:
- Modern Rheumatology Case Reports, 2024, v. 8, n. 1, p. 74, doi. 10.1093/mrcr/rxad061
- By:
- Publication type:
- Article
Five cases of seronegative persistent inflammatory monoarthritis improved with biological therapy.
- Published in:
- Modern Rheumatology Case Reports, 2023, v. 7, n. 1, p. 307, doi. 10.1093/mrcr/rxac063
- By:
- Publication type:
- Article
A rheumatoid arthritis patient with delivery who started certolizumab pegol and tacrolimus during pregnancy.
- Published in:
- Modern Rheumatology Case Reports, 2022, v. 6, n. 1, p. 6, doi. 10.1093/mrcr/rxab005
- By:
- Publication type:
- Article
Minimal change nephrotic syndrome due to certolizumab pegol, an anti-tumor necrosis factor-alpha monoclonal antibody for treatment of rheumatoid arthritis.
- Published in:
- Rheumatology Advances in Practice, 2022, v. 6, n. 1, p. 1, doi. 10.1093/rap/rkac012
- By:
- Publication type:
- Article
Renal sarcoidosis associated with certolizumab pegol treatment for psoriatic arthritis.
- Published in:
- Oxford Medical Case Reports, 2022, v. 2022, n. 12, p. 1, doi. 10.1093/omcr/omac133
- By:
- Publication type:
- Article
Comparisons of infection events associated with tumor necrosis factor inhibitors in patients with inflammatory arthritis: A systematic review and network meta-analysis.
- Published in:
- Frontiers in Pharmacology, 2024, p. 1, doi. 10.3389/fphar.2024.1376262
- By:
- Publication type:
- Article
Multi‐failure psoriasis patients: characterization of the patients and response to biological therapy in a multicenter Italian cohort.
- Published in:
- International Journal of Dermatology, 2024, v. 63, n. 3, p. 351, doi. 10.1111/ijd.17005
- By:
- Publication type:
- Article
Development of cutaneous T‐cell lymphoma following exposure to biologic therapy: a Mayo Clinic retrospective analysis.
- Published in:
- International Journal of Dermatology, 2023, v. 62, n. 7, p. e371, doi. 10.1111/ijd.16386
- By:
- Publication type:
- Article
A case of psoriatic alopecia secondary to certolizumab pegol: clinical and trichoscopic evaluation.
- Published in:
- International Journal of Dermatology, 2023, v. 62, n. 2, p. e70, doi. 10.1111/ijd.16275
- By:
- Publication type:
- Article
Certolizumab pegol and its role in pregnancy‐age hidradenitis suppurativa.
- Published in:
- International Journal of Dermatology, 2022, v. 61, n. 5, p. e182, doi. 10.1111/ijd.15742
- By:
- Publication type:
- Article
Exploring the impact of the national tender system on the use of costly drugs treating rheumatoid arthritis patients in ten rheumatology centers in Norway (2010–2019).
- Published in:
- BMC Health Services Research, 2023, v. 23, n. 1, p. 1, doi. 10.1186/s12913-023-09975-7
- By:
- Publication type:
- Article
Comparative analysis of low-field magnetic resonance imaging in patients with rheumatoid arthritis treated with certolizumab pegol or infliximab.
- Published in:
- Modern Rheumatology, 2023, v. 33, n. 6, p. 1097, doi. 10.1093/mr/roac138
- By:
- Publication type:
- Article
Safety and effectiveness of certolizumab pegol in Japanese patients with rheumatoid arthritis: Results from a 24-week post-marketing surveillance study.
- Published in:
- Modern Rheumatology, 2023, v. 33, n. 3, p. 460, doi. 10.1093/mr/roac073
- By:
- Publication type:
- Article
Safety and effectiveness of certolizumab pegol in Japanese patients with rheumatoid arthritis: Results from a 24-week post-marketing surveillance study.
- Published in:
- Modern Rheumatology, 2023, v. 33, n. 3, p. 460, doi. 10.1093/mr/roac073
- By:
- Publication type:
- Article
Non-trough adalimumab and certolizumab drug levels associated with a therapeutic EULAR response in adherent patients with rheumatoid arthritis.
- Published in:
- Rheumatology, 2023, v. 62, n. 6, p. 2090, doi. 10.1093/rheumatology/keac564
- By:
- Publication type:
- Article
Certolizumab to treat hidradenitis suppurativa.
- Published in:
- 2023
- By:
- Publication type:
- Case Study
Monoclonal Antibody Therapy for the Treatment of Interstitial Cystitis.
- Published in:
- Biologics: Targets & Therapy, 2022, v. 16, p. 47, doi. 10.2147/BTT.S290286
- By:
- Publication type:
- Article
A genome-wide screen for variants influencing certolizumab pegol response in a moderate to severe rheumatoid arthritis population.
- Published in:
- PLoS ONE, 2022, v. 17, n. 4, p. 1, doi. 10.1371/journal.pone.0261165
- By:
- Publication type:
- Article
Focus on Anti-Tumour Necrosis Factor (TNF)-α-Related Autoimmune Diseases.
- Published in:
- International Journal of Molecular Sciences, 2023, v. 24, n. 9, p. 8187, doi. 10.3390/ijms24098187
- By:
- Publication type:
- Article
Certolizumab Pegol for the Treatment of Plaque Psoriasis in Routine Clinical Practice: One-Year Results from the CIMREAL Study.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 8, p. 2077, doi. 10.1007/s13555-024-01210-3
- By:
- Publication type:
- Article
Letter to the Editor: Response to Fitzgerald T et al. Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA.
- Published in:
- Dermatology & Therapy, 2023, v. 13, n. 11, p. 2911, doi. 10.1007/s13555-023-01015-w
- By:
- Publication type:
- Article
Drug Survival of Tumor Necrosis Factor-Alpha Inhibitors and Switched Subsequent Biologic Agents in Patients with Psoriasis: A Retrospective Study.
- Published in:
- Dermatology & Therapy, 2023, v. 13, n. 6, p. 1347, doi. 10.1007/s13555-023-00932-0
- By:
- Publication type:
- Article
Publisher Correction: Long-Term Health-Related Quality of Life in Patients with Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Randomised Phase 3 Studies (CIMPASI-1 and CIMPASI-2).
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Long-Term Health-Related Quality of Life in Patients with Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Randomised Phase 3 Studies (CIMPASI-1 and CIMPASI-2).
- Published in:
- Dermatology & Therapy, 2023, v. 13, n. 1, p. 315, doi. 10.1007/s13555-022-00861-4
- By:
- Publication type:
- Article
Treatment Patterns for Targeted Therapies, Non-Targeted Therapies, and Drug Holidays in Patients with Psoriasis.
- Published in:
- Dermatology & Therapy, 2022, v. 12, n. 9, p. 2087, doi. 10.1007/s13555-022-00775-1
- By:
- Publication type:
- Article
Efficacy and Safety of Certolizumab Pegol in Japanese Patients with Generalized Pustular Psoriasis and Erythrodermic Psoriasis: 52-Week Results.
- Published in:
- Dermatology & Therapy, 2022, v. 12, n. 6, p. 1397, doi. 10.1007/s13555-022-00741-x
- By:
- Publication type:
- Article
Characteristic analysis of adverse reactions of five anti-TNFɑ agents: a descriptive analysis from WHO-VigiAccess.
- Published in:
- Frontiers in Pharmacology, 2023, p. 1, doi. 10.3389/fphar.2023.1169327
- By:
- Publication type:
- Article
Growth in the Cost of Biologics in Medicare Beneficiaries, 2017 to 2019.
- Published in:
- Journal of Clinical & Aesthetic Dermatology, 2024, v. 17, n. 7, p. 17
- By:
- Publication type:
- Article
Tumor necrosis factor inhibitors and janus kinase inhibitors in the treatment of cicatricial alopecia: A systematic review.
- Published in:
- PLoS ONE, 2024, v. 19, n. 2, p. 1, doi. 10.1371/journal.pone.0293433
- By:
- Publication type:
- Article
Rheumatoid factor titers, but not Fc fragments, may be strongly associated with drug survival of anti-TNF agents in patients with rheumatoid arthritis.
- Published in:
- Northern Clinics of Istanbul, 2024, v. 11, n. 2, p. 147, doi. 10.14744/nci.2023.01643
- By:
- Publication type:
- Article
Complex decongestive therapy in hidradenitis suppurativa-related genital lymphoedema: a case report.
- Published in:
- Journal of Wound Care, 2024, v. 33, n. Sup2a, p. xxviii, doi. 10.12968/jowc.2024.33.Sup2a.xxviii
- By:
- Publication type:
- Article
Methotrexate Safety and Efficacy in Combination Therapies in Patients With Early Rheumatoid Arthritis: A Post Hoc Analysis of a Randomized Controlled Trial.
- Published in:
- Arthritis & Rheumatology, 2024, v. 76, n. 3, p. 363, doi. 10.1002/art.42730
- By:
- Publication type:
- Article
Certolizumab pegol in the treatment of severe hidradenitis suppurativa after adalimumab failure: A real‐life experience.
- Published in:
- Dermatologic Therapy, 2022, v. 35, n. 11, p. 1, doi. 10.1111/dth.15782
- By:
- Publication type:
- Article
Refractory folliculitis decalvans treated with biologics: Case series in 4 situations.
- Published in:
- Dermatologic Therapy, 2022, v. 35, n. 10, p. 1, doi. 10.1111/dth.15778
- By:
- Publication type:
- Article
Certolizumab pegol as an alternative treatment in patients with coexisting hidradenitis suppurativa and other inflammatory immune‐mediated diseases: Report of two cases.
- Published in:
- Dermatologic Therapy, 2022, v. 35, n. 5, p. 1, doi. 10.1111/dth.15401
- By:
- Publication type:
- Article
Vliv pohlaví na závažnost onemocnĕní a terapeutickou odpovĕď u pacientů s revmatoidní artritidou, axiální spondyloartritidou a psoriatickou artritidou léčených jeden rok certolizumab peIolem - analýza z národního registru biologické léčby ATTRA
- Published in:
- Czech Rheumatology / Česká Revmatologie, 2021, v. 29, n. 4, p. 191
- By:
- Publication type:
- Article
Granulomatous Hepatitis Treated With Certolizumab Pegol.
- Published in:
- ACG Case Reports Journal, 2024, v. 11, n. 4, p. 1, doi. 10.14309/crj.0000000000001310
- By:
- Publication type:
- Article
P74: A review of pregnancy discussions and outcomes in the biologics for psoriasis cohort at our local trust.
- Published in:
- British Journal of Dermatology, 2022, v. 187, p. 67, doi. 10.1111/bjd.21196
- Publication type:
- Article
Pharmacokinetics of Monoclonal Antibodies Throughout Pregnancy: A Systematic Literature Review.
- Published in:
- Clinical Pharmacokinetics, 2024, v. 63, n. 5, p. 589, doi. 10.1007/s40262-024-01370-7
- By:
- Publication type:
- Article
Tumor Necrosis Factor a Inhibitor-Induced Lupuslike Syndrome in a Patient Prescribed Certolizumab Pegol.
- Published in:
- Cutis, 2022, v. 109, n. 6, p. E18, doi. 10.12788/cutis.0554
- By:
- Publication type:
- Article
Drug Adherence and Persistence of Patients with Moderate to Severe Psoriasis Treated with Biologic Medications in a US Commercially Insured Population.
- Published in:
- Dermatology (10188665), 2022, v. 238, n. 3, p. 438, doi. 10.1159/000519176
- By:
- Publication type:
- Article
Long-Term Durability of Certolizumab Pegol in Patients with Rheumatoid Arthritis Over 5 Years: An Analysis of Pooled Clinical Trial Data.
- Published in:
- Rheumatology & Therapy, 2023, v. 10, n. 3, p. 693, doi. 10.1007/s40744-023-00541-5
- By:
- Publication type:
- Article
Comparative Efficacy of Biologic Disease-Modifying Anti-Rheumatic Drugs for Non-Radiographic Axial Spondyloarthritis: A Systematic Literature Review and Bucher Indirect Comparisons.
- Published in:
- Rheumatology & Therapy, 2023, v. 10, n. 2, p. 307, doi. 10.1007/s40744-022-00522-0
- By:
- Publication type:
- Article
Certolizumab Pegol Treatment in Patients with Axial-Spondyloarthritis-Associated Acute Anterior Uveitis: a Narrative Review.
- Published in:
- Rheumatology & Therapy, 2022, v. 9, n. 6, p. 1481, doi. 10.1007/s40744-022-00486-1
- By:
- Publication type:
- Article
Association between TNFi anti-drug antibodies, smoking, and disease activity in patients with inflammatory arthritis: Results from a Norwegian cross-sectional observational study.
- Published in:
- Rheumatology & Therapy, 2022, v. 9, n. 4, p. 1171, doi. 10.1007/s40744-022-00464-7
- By:
- Publication type:
- Article